The National Medical Products Administration has issued the Guiding Opinions on the Standardized Development of Modern Pharmaceutical Logistics (No. 7/2026), establishing a unified regulatory framework aimed at advancing a more digitalised, traceable, and compliant pharmaceutical supply chain across China.
The Guiding Opinions place particular emphasis on end-to-end traceability, the integration of ERP, WMS, and transportation management systems, enhanced warehousing and cold-chain controls, and strengthened obligations relating to cybersecurity, data governance, and data integrity. The measures reflect the regulator’s broader objective of promoting greater operational standardisation and transparency throughout the pharmaceutical distribution lifecycle.
